Quantum-Dot-Based Theranostic Micelles Conjugated with an Anti-EGFR Nanobody for Triple-Negative Breast Cancer Therapy.
Yuyuan WangYidan WangGuojun ChenYitong LiWei XuShaoqin GongPublished in: ACS applied materials & interfaces (2017)
A quantum-dot (QD)-based micelle conjugated with an anti-epidermal growth factor receptor (EGFR) nanobody (Nb) and loaded with an anticancer drug, aminoflavone (AF), has been engineered for EGFR-overexpressing cancer theranostics. The near-infrared (NIR) fluorescence of the indium phosphate core/zinc sulfide shell QDs (InP/ZnS QDs) allowed for in vivo nanoparticle biodistribution studies. The anti-EGFR nanobody 7D12 conjugation improved the cellular uptake and cytotoxicity of the QD-based micelles in EGFR-overexpressing MDA-MB-468 triple-negative breast cancer (TNBC) cells. In comparison with the AF-encapsulated nontargeted (i.e., without Nb conjugation) micelles, the AF-encapsulated Nb-conjugated (i.e., targeted) micelles accumulated in tumors at higher concentrations, leading to more effective tumor regression in an orthotopic triple-negative breast cancer xenograft mouse model. Furthermore, there was no systemic toxicity observed with the treatments. Thus, this QD-based Nb-conjugated micelle may serve as an effective theranostic nanoplatform for EGFR-overexpressing cancers such as TNBCs.
Keyphrases
- epidermal growth factor receptor
- cancer therapy
- tyrosine kinase
- photodynamic therapy
- drug delivery
- small cell lung cancer
- advanced non small cell lung cancer
- drug release
- mouse model
- atrial fibrillation
- fluorescence imaging
- cell cycle arrest
- oxidative stress
- single molecule
- signaling pathway
- drug induced
- high resolution
- pet imaging
- positron emission tomography
- oxide nanoparticles
- squamous cell
- electronic health record
- pet ct
- adverse drug